Calendrier des promotions Bristol-Myers Squibb Company PFD CONV 2
Calendrier avancé
Graphique simple
À propos de l'entreprise Bristol-Myers Squibb Company PFD CONV 2
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.Paramètres de base
ISIN
US1101222073
Валюта
usd
Валюта отчета
usd
Див.доход ао
0.2405
Дивиденд ао
0.5
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 41.92 | 1 |
P/BV | 123.55 | 1 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -9.53 | 0 |
ROE | -39.1 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0.2884 | 0.73 |
DSI | 0.9286 | 9.29 |
Croissance moyenne du dividende | 1.62 | 2.69 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | 15.91 | 0 |
Debt/Ratio | 0.5529 | 9 |
Debt/Equity | 4.65 | 1 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 13.6 | 2 |
Rentabilité Ebitda, % | -78.27 | 0 |
Rentabilité EPS, % | 58.65 | 7 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 811.11 $ | 0 $ | 0 $ | -6.3 % | 0 % | 0 % |
common.calendar.number_days.7d | 840.11 $ | 0 $ | 0 $ | -9.54 % | 0 % | 0 % |
common.calendar.number_days.30d | 790 $ | 760 $ | 898.98 $ | -3.8 % | 0 % | 0 % |
common.calendar.number_days.90d | 875 $ | 752 $ | 1 003.2 $ | -13.14 % | 0 % | 0 % |
common.calendar.number_days.180d | 978 $ | 752 $ | 1 065.75 $ | -22.29 % | 0 % | 0 % |
common.calendar.number_days.1y | 810 $ | 735.5 $ | 1 065.75 $ | -6.17 % | 0 % | 0 % |
common.calendar.number_days.3y | 700 $ | 700 $ | 1 450 $ | 115.87 % | 0 % | 0 % |
common.calendar.number_days.5y | 700 $ | 700 $ | 2 000 $ | 115.87 % | 0 % | 0 % |
common.calendar.number_days.10y | 700 $ | 700 $ | 2 000 $ | 115.87 % | 0 % | 0 % |
common.calendar.number_days.ytd | 946 $ | 752 $ | 1 065.75 $ | -19.66 % | 0 % | 0 % |